NextCure’s (NXTC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of NextCure (NASDAQ:NXTC) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

NextCure Stock Performance

NASDAQ NXTC opened at $0.58 on Monday. The firm’s 50 day moving average price is $0.76 and its 200-day moving average price is $1.07. NextCure has a 52-week low of $0.55 and a 52-week high of $2.57. The company has a market cap of $16.22 million, a PE ratio of -0.28 and a beta of 0.71.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, analysts forecast that NextCure will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

Several institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC boosted its stake in NextCure by 40.6% in the fourth quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock valued at $61,000 after acquiring an additional 22,724 shares in the last quarter. Geode Capital Management LLC boosted its stake in NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after acquiring an additional 27,812 shares in the last quarter. Tang Capital Management LLC boosted its stake in NextCure by 7.3% in the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after acquiring an additional 47,614 shares in the last quarter. Renaissance Technologies LLC boosted its stake in NextCure by 27.9% in the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after acquiring an additional 113,300 shares in the last quarter. Finally, Peapod Lane Capital LLC acquired a new stake in NextCure in the fourth quarter valued at approximately $311,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.